ArticleFrontiers in oncology2025

Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a real-world retrospective study.

Jingjing Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.